Lee, J.C. et al. 2021. Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan. Asian Pacific Journal of Cancer Biology. 6, 2 (May 2021), 123–132. DOI:https://doi.org/10.31557/apjcb.2021.6.2.123-132.